查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1425073

癌症惡病質市場：預測（2024-2029）

Cancer Cachexia Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

到2022年，癌症惡病質市場價值將達到2,058,952,000美元，複合年成長率為4.78%，到2029年市場規模將達到2,854,926,000美元。

癌症惡病質的特徵是食慾下降和肌肉萎縮。它是多因素造成的，可能是由宿主吞噬細胞活性、無意的體重減輕、不平衡的蛋白質飲食和慢性發炎引起的。癌症惡病質的治療方法包括黃體素和皮質類固醇。黃體酮是一種合成或天然類固醇激素。

癌症惡病質市場促進因素

癌症和癌症惡病質盛行率上升等因素正在增加對藥物和治療藥物的需求。癌症惡病質市場對藥物的需求不斷成長，推動了新治療藥物的研發活動。這些因素在癌症惡病質市場的成長中發揮著重要作用。此外，由於對癌症惡病質的了解不斷增加以及癌症惡病質治療方法的開拓，癌症惡病質市場也不斷成長。

癌症盛行率增加

世界各地癌症的盛行率正在增加。根據世界衛生組織2022年2月發布的消息，每年有40萬名兒童被診斷出患有癌症，而且最常見的惡性因國家而異。因此，癌症患者以全身性發炎、蛋白質和能源平衡以及無意識的去脂體重損失為特徵的癌症惡病質的發生率正在增加。這種成長推動了癌症惡病質市場的成長。

更多地使用跨學科方法和開發

根據美國國家生物技術資訊中心 (NCBI) 的報告，大約一半的癌症患者會出現癌症惡病質，即脂肪組織和骨骼肌質量逐漸喪失。惡病質症候群對患者的生活品質、化療等治療的不良結果以及較低的存活率有顯著影響。惡病質採用外源性食慾興奮劑治療，重點在於緩解症狀和減輕患者痛苦。早期治療方法並不是很成功，因為儘管需要多管齊下的策略，但它們只能解決疾病的一部分。

可能存在藥物

儘管治療結果存在臨床差距，但市面上有多種藥物已被證明可以成功治療癌症引起的惡病質。目前，還沒有專門針對癌症惡病質的核准藥物。這擴大了治療選擇的差距，產業參與者正在努力透過研發以及將新藥引入全球癌症惡病質市場來縮小這一差距。

擴大聯合治療的接受度

聯合治療採用新型治療藥物，如醋酸甲地孕酮、甲羥孕酮、生長素釋放Ghrelin和Omega-3脂肪酸，並與飲食調整和運動相結合。由於治療方法的改進，癌症惡病質行業預計將成長。

Helsinn 是一家瑞士製藥公司，開發領先的癌症和罕見疾病治療藥物，與小野製藥合作治療惡性非小細胞肺癌、胃癌、胰腺癌和大腸。我們宣布將推出該液治療藥物Adormizo（anamorelin）將於2021 年首次在日本上市。

加大研發力度

由於世界各地的癌症患者中癌症惡病質的發生率很高，臨床研究的重點是確定各種人類惡性中癌症惡病質的特徵。為了改善癌症預後，有必要了解伴隨癌症惡病質進展的肌肉無力背後的分子過程。因此，存在著龐大的產品平臺，並且大量的研究和開發正在進行中。

在北美，癌症惡病質市場預計將穩定成長。

癌症惡病質市場預計將佔據北美最大的市場佔有率。該地區的主導地位是由於癌症惡病質盛行率不斷上升以及癌症支持性護理知識的不斷擴展。該地區的特點是患者可以獲得良好的報銷系統以及較高的價格。由於人們對該疾病的認知不斷提高以及對治療的需求不斷增加，歐洲癌症惡病質產業預計將以高成長率成長。此外，歐洲癌症惡病質市場參與企業在供應鏈升級和新藥上市方面投入大量資金，預計將推動市場成長。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表

第2章調查方法

  • 調查資料
  • 先決條件

第3章執行摘要

  • 研究亮點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析

第5章癌症惡病質市場：依治療方法

  • 介紹
  • 黃體素
  • 皮質類固醇
  • 聯合治療
  • 其他

第6章癌症惡病質市場：依作用機制

  • 介紹
  • 食慾興奮劑
  • 減重穩定劑

第7章癌症惡病質市場：依通路

  • 介紹
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章癌症惡病質市場：依地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 其他
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作

第10章 公司簡介

  • Actimed Therapeutics
  • Pephexia Therapeutics
  • Pfizer
  • Ono Pharma
  • Helsinn Group
  • Merck KGaA
  • Aveo Oncology
  • Tetra Bio-Pharma
簡介目錄
Product Code: KSI061616140

The cancer cachexia market is evaluated at US$2,058.952 million for the year 2022 growing at a CAGR of 4.78% reaching the market size of US$2,854.926 million by the year 2029.

Cancer cachexia is characterized by a decrease in appetite and muscular wasting. It is multifactorial and may be brought on by host phagocytic activity, unintentional weight loss, an unbalanced protein diet, and chronic inflammation. Treatment options for cancer cachexia include progestogens and corticosteroids. Progesterone is a steroid hormone that can be either synthetic or natural.

Driving factors for the cancer cachexia market

There has been a rise in demand for medications and treatment due to factors including the rising incidence of cancer and cancer cachexia in patients. The cancer cachexia market's increasing need for medicines has increased R&D efforts to create new therapeutic medications. These elements play a significant role in the cancer cachexia market growth. Additionally, the cancer cachexia market has grown as a result of greater knowledge of this illness and developments in the treatment of cancer cachexia.

Growing prevalence of cancer

The prevalence of cancer is rising worldwide. According to information released by the WHO in February 2022, 400,000 children are diagnosed with cancer each year, and the most prevalent malignancies differ by country. As a result, the occurrence of cancer cachexia, which is characterized by systemic inflammation, a negative protein and energy balance, and an unintentional loss of lean body mass, is rising among cancer patients. This rise is fueling the cancer cachexia market growth.

Increasing use of multidisciplinary approach and development

The National Centre for Biotechnology Information (NCBI) reports that cancer cachexia, which causes a gradual loss of adipose tissue and skeletal muscle mass, will develop in around half of all cancer patients. Patient quality of life is significantly affected by cachexia syndrome, which also has poor outcomes from therapies like chemotherapy and lower survival rates. Treatments for cachexia involve exogenic appetite stimulants, with an emphasis on symptom palliation and patient distress reduction. The earlier treatments were not very successful since they just addressed one part of this illness when a multifaceted strategy was required.

Presence of potential drugs

Various drugs are present in the market that have proven to be successful in treating cancer-induced cachexia, despite a clinical gap in the treatment results. There isn't presently a drug being approved specifically to deal with cancer cachexia. This widens the gap in treatment options, which industry players are attempting to narrow through R&D and the introduction of new drugs onto the global cancer cachexia market.

Increasing acceptance of combination treatments

Current treatments for cachexia use a multidisciplinary approach; combination therapy, which incorporates novel therapeutic agents including megestrol acetate, medroxyprogesterone, ghrelin, and omega-3 fatty acids, among others, has been merged with dietary changes and exercise. The cancer cachexia industry is anticipated to grow as a result of improvements in treatment methods.

Helsinn, a Swiss pharmaceutical company that creates top-notch cancer care and rare disease products, partnered with Ono Pharmaceutical to announce the first launch of Adlumizo (anamorelin) in Japan in 2021 to treat cancer cachexia in malignant non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer.

Increase in research & development

A growing amount of focus has been placed on clinical investigations to pinpoint the features of cancer cachexia across a variety of human malignancies due to the high frequency of cancer cachexia instances among cancer patients worldwide. To improve cancer outcomes, it is vital to understand the molecular processes behind muscle loss as cancer cachexia progresses. As a result, there is a huge pipeline of products and considerable R&D operations underway.

In North America, it is projected that the cancer cachexia market will grow steadily.

The cancer cachexia market is anticipated to hold the maximum market share in North America. The dominance of this region is a result of the rising incidence of cancer cachexia and expanding knowledge of cancer-supportive therapies. This location is distinguished by a higher degree of affordability as well as the availability of patients with adequate reimbursement plans. The cancer cachexia industry in Europe is predicted to grow at a high growth rate due to rising awareness of the condition and rising treatment demand. Additionally, due to cancer cachexia market participants in Europe making sizeable expenditures to upgrade their supply chains and launch new pharmaceuticals, the market is anticipated to grow.

Market Key Developments

  • In June 2023, Actimed Therapeutics Ltd., a clinical-stage specialty pharmaceutical business located in the UK, secured more than £5 million in an oversubscribed Series A investment round. The firm is dedicated to bringing innovation to the treatment of cancer cachexia and kindred muscle-wasting conditions.
  • In September 2022, The multi-year agreement between CytoReason and Pfizer has been extended, and Pfizer will be able to use CytoReason's AI technology in its drug development initiatives.
  • In June 2022, A $25 million Cancer Grand Challenges grant has been given to Weill Cornell Medicine, the Rutgers Cancer Institute of New Jersey, and Cold Spring Harbour Laboratory to address cancer cachexia, the crippling wasting disease that accounts for up to 30% of cancer-related fatalities.

Segmentation:

By Therapeutics

  • Progestogens
  • Corticosteroids
  • Combination Therapy
  • Others

By Mechanism of Action

  • Appetite Stimulators
  • Weight Loss Stabilizers

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. CANCER CACHEXIA MARKET, BY THERAPEUTICS

  • 5.1. Introduction
  • 5.2. Progestogens
  • 5.3. Corticosteroids
  • 5.4. Combination Therapy
  • 5.5. Others

6. CANCER CACHEXIA MARKET, BY MECHANISM OF ACTION

  • 6.1. Introduction
  • 6.2. Appetite Stimulators
  • 6.3. Weight Loss Stabilizers

7. CANCER CACHEXIA MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Retail Pharmacy
  • 7.4. Online Pharmacy

8. CANCER CACHEXIA MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. Actimed Therapeutics
  • 10.2. Pephexia Therapeutics
  • 10.3. Pfizer
  • 10.4. Ono Pharma
  • 10.5. Helsinn Group
  • 10.6. Merck KGaA
  • 10.7. Aveo Oncology
  • 10.8. Tetra Bio-Pharma